Objective To provide a meta-analysis of the available randomized clinical trials (RCTs) reporting the impact of 5-alpha reductase inhibitors treatment for BPH on erectile function. Methods According to the requirements of meta-analysis, a literature search about 5-alpha reductase inhibitors therapy in BPH was performed among PubMed, EMBASE, Science Direct and The Cochrane Library from the establishment of the database till June 2016．Rresults A total of 391 articles were included, 11 RCTs were enrolled for meta-analysis. All articles used randomized, double blind and placebo control. Within 1 year, erectile dysfunction was more common with 5-alpha reductase inhibitors than with placebo (OR=2.18, P<0.00001). In particular, considering Finasteride (OR=2.28, P<0.00001) or Dutasteride (OR=2.06, P<0.00001). Finasteride had no significantly difference with Dutasteride. In more than 1 year, erectile dysfunction was more common with 5-alpha reductase inhibitors than with placebo (OR=1.45, P<0.0001). In particular, considering Finasteride (OR=1.46, P<0.0001); conversely, Dutasteride was associated with a risk similar to placebo. Conclusion Within 1 year, 5-Alpha reductase inhibitors may increase the risk of erectile dysfunction. In more than 1 year, Finasteride was more likely to lead to erectile dysfunction. These data can be relevant both for drug selection and patients counseling.
| Published in | International Journal of Clinical Urology (Volume 1, Issue 1) |
| DOI | 10.11648/j.ijcu.20170101.11 |
| Page(s) | 1-6 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2017. Published by Science Publishing Group |
5-Alpha Reductase Inhibitors, Benign Prostatic Hyperplasia, Erectile Dysfunction, Meta-Analysis
| [1] | Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia [J]. J Urol, 2004, 172 (5): 1784-1791. |
| [2] | Li-ming Pang. Research Progress on etiology, diagnosis and treatment of benign prostatic hyperplasia [J]. China Academic Journal Electronic Publishing House, 2011, 9 (20): 233-235. |
| [3] | Hao-yong L, Bo Hu, Ji-hong Liu. Drug therapy for benign prostatic hyperplasia [J]. Herald of Medicine, 2011, 30( 14): 4145. |
| [4] | Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia [J]. World J Urol, 2002 Apr, 19 (6): 413-25. |
| [5] | Corona G, Rastrelli G, Maseroli E, et al. Sexual function of the ageing male [J]. Best Pract Res Clin Endocrinol Metab, 2013 Aug, 27 (4): 581-601. |
| [6] | Ortiz-Gómez JR, Carrascosa F, Pérez-Cajaraville JJ, et al. Comparative study of intubating conditions at the first minute with suxamethonium, rocuronium and different priming techniques of rocuronium [J]. Eur J Anaesthesiol, 2005 Apr, 22 (4): 263-8. |
| [7] | Yavaşcaoğlu B, Cebelli V, Kelebek N, et al. Comparison of different priming techniques on the onset time and intubating conditions of rocuronium [J]. Eur J Anaesth, 2002, 19 (7): 517-521. |
| [8] | Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group [J]. Urology. 1995 Nov; 46 (5): 631-7. |
| [9] | Byrnes CA, Morton AS, Liss CL, et al. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar [J]. Clin Ther. 1995 Sep-Oct; 17 (5): 956-69. |
| [10] | Roehrborn CG, Lee M, Meehan A, et al. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia [J]. Urology. 2003 Nov; 62 (5): 894-9. |
| [11] | Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group [J]. Urology. 1998 May; 51 (5): 677-86. |
| [12] | Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study [J]. CMAJ. 1996 Nov 1; 155 (9): 1251-9. |
| [13] | Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia[J]. The New England Journal of Medicine, 1992 Oct, 17 (327): 1185-91. |
| [14] | Roehrborn CG, Ray P. Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men [J]. Prostate Cancer Prostatic Dis. 2006; 9 (4): 432-8. |
| [15] | Tsukamoto T, Endo Y, Narita M. Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia [J]. Int J Urol. 2009 Sep; 16 (9): 745-50. |
| [16] | Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia [J]. Urology. 2002 Sep; 60 (3): 434-41. |
| [17] | Nickel JC, Gilling P, Tammela TL, et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS) [J]. BJU Int. 2011 Aug; 108 (3): 388-94. |
| [18] | Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor [J]. J Clin Endocrinol Metab. 2004 May; 89 (5): 2179-84. |
| [19] | McConnell JD, Brusketwitz R, Walsh P, Andriole G, Lieber M, Holtgrewe L, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998; 338: 557– 63. 1986, 29: 2298–315. |
| [20] | Food and Drug Administration. Oncologic Drugs Advisory Committee-2010 Meeting Materials, Oncologic Drugs Advisory Committee. 2010 |
| [21] | Lugg JA, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat [J]. Endocrinology. 1995; 136: 1495–501. |
| [22] | Pinsky MR, Gur S, Tracey AJ, et al. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function [J]. J Sex Med. 2011; 8: 3066–74. |
| [23] | Zhang MG, Wang XJ, Shen ZJ, et al. Long-term oral administration of 5alpha-reductase inhibitor attenuates erectile function by inhibiting autophagy and promoting apoptosis of smooth muscle cells in corpus cavernosum of aged rats [J]. Urology. 2013; 82: 743. |
APA Style
He Xiao, Hu Lei, Fang Qing-hua, Chen Dong. (2017). Impact of 5-Alpha Reductase Inhibitors Treatment for Benign Prostatic Hyperplasia on Erectile Dysfunction: A Meta-Analysis. International Journal of Clinical Urology, 1(1), 1-6. https://doi.org/10.11648/j.ijcu.20170101.11
ACS Style
He Xiao; Hu Lei; Fang Qing-hua; Chen Dong. Impact of 5-Alpha Reductase Inhibitors Treatment for Benign Prostatic Hyperplasia on Erectile Dysfunction: A Meta-Analysis. Int. J. Clin. Urol. 2017, 1(1), 1-6. doi: 10.11648/j.ijcu.20170101.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijcu.20170101.11,
author = {He Xiao and Hu Lei and Fang Qing-hua and Chen Dong},
title = {Impact of 5-Alpha Reductase Inhibitors Treatment for Benign Prostatic Hyperplasia on Erectile Dysfunction: A Meta-Analysis},
journal = {International Journal of Clinical Urology},
volume = {1},
number = {1},
pages = {1-6},
doi = {10.11648/j.ijcu.20170101.11},
url = {https://doi.org/10.11648/j.ijcu.20170101.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20170101.11},
abstract = {Objective To provide a meta-analysis of the available randomized clinical trials (RCTs) reporting the impact of 5-alpha reductase inhibitors treatment for BPH on erectile function. Methods According to the requirements of meta-analysis, a literature search about 5-alpha reductase inhibitors therapy in BPH was performed among PubMed, EMBASE, Science Direct and The Cochrane Library from the establishment of the database till June 2016．Rresults A total of 391 articles were included, 11 RCTs were enrolled for meta-analysis. All articles used randomized, double blind and placebo control. Within 1 year, erectile dysfunction was more common with 5-alpha reductase inhibitors than with placebo (OR=2.18, P<0.00001). In particular, considering Finasteride (OR=2.28, P<0.00001) or Dutasteride (OR=2.06, P<0.00001). Finasteride had no significantly difference with Dutasteride. In more than 1 year, erectile dysfunction was more common with 5-alpha reductase inhibitors than with placebo (OR=1.45, P<0.0001). In particular, considering Finasteride (OR=1.46, P<0.0001); conversely, Dutasteride was associated with a risk similar to placebo. Conclusion Within 1 year, 5-Alpha reductase inhibitors may increase the risk of erectile dysfunction. In more than 1 year, Finasteride was more likely to lead to erectile dysfunction. These data can be relevant both for drug selection and patients counseling.},
year = {2017}
}
TY - JOUR T1 - Impact of 5-Alpha Reductase Inhibitors Treatment for Benign Prostatic Hyperplasia on Erectile Dysfunction: A Meta-Analysis AU - He Xiao AU - Hu Lei AU - Fang Qing-hua AU - Chen Dong Y1 - 2017/01/24 PY - 2017 N1 - https://doi.org/10.11648/j.ijcu.20170101.11 DO - 10.11648/j.ijcu.20170101.11 T2 - International Journal of Clinical Urology JF - International Journal of Clinical Urology JO - International Journal of Clinical Urology SP - 1 EP - 6 PB - Science Publishing Group SN - 2640-1355 UR - https://doi.org/10.11648/j.ijcu.20170101.11 AB - Objective To provide a meta-analysis of the available randomized clinical trials (RCTs) reporting the impact of 5-alpha reductase inhibitors treatment for BPH on erectile function. Methods According to the requirements of meta-analysis, a literature search about 5-alpha reductase inhibitors therapy in BPH was performed among PubMed, EMBASE, Science Direct and The Cochrane Library from the establishment of the database till June 2016．Rresults A total of 391 articles were included, 11 RCTs were enrolled for meta-analysis. All articles used randomized, double blind and placebo control. Within 1 year, erectile dysfunction was more common with 5-alpha reductase inhibitors than with placebo (OR=2.18, P<0.00001). In particular, considering Finasteride (OR=2.28, P<0.00001) or Dutasteride (OR=2.06, P<0.00001). Finasteride had no significantly difference with Dutasteride. In more than 1 year, erectile dysfunction was more common with 5-alpha reductase inhibitors than with placebo (OR=1.45, P<0.0001). In particular, considering Finasteride (OR=1.46, P<0.0001); conversely, Dutasteride was associated with a risk similar to placebo. Conclusion Within 1 year, 5-Alpha reductase inhibitors may increase the risk of erectile dysfunction. In more than 1 year, Finasteride was more likely to lead to erectile dysfunction. These data can be relevant both for drug selection and patients counseling. VL - 1 IS - 1 ER -
Information
Email: